🇺🇸 FDA
Patent

US 10285988

Compounds for treatment of fibrosis diseases

granted A61KA61K31/444A61K31/4725

Quick answer

US patent 10285988 (Compounds for treatment of fibrosis diseases) held by Curegenix, Inc. expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Curegenix, Inc.
Grant date
Tue May 14 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K31/444, A61K31/4725, A61K31/497, A61K31/4985